MindMed Archives

Psychedelics News

MindMed

Industry

18 May 2023

MindMed Announces Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

MindMed announced that the company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for GAD is over 50% enrolled and dosed....

By Microdose NewsDesk

Finance

8 May 2023

Which Psychedelic Medicine Companies Have the Best Financials?

As I have written many times before, the success or failure of a psychedelic medicine company depends heavily on its financial position....

By James Hallifax

Industry

3 May 2023

MindMed Drama: Freemans Attempt Board of Directors Takeover

The drama continues at MindMed. The (former?) fan-favorite has had a rough run, facing an industry-wide drop in share price while dealing with a string of scenarios that have (rightly...

By Jason Najum

Science

26 Apr 2023

What is LSD? A Look at LSD Clinical Trials

To celebrate Bicycle Day, Microdose is devoting the month of April to an exploration of LSD. To help answer the question of what is LSD? we’re taking a closer look...

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

14 Apr 2023

MindMed Announces Positive Data from Phase 2 LSD Trial for Depression

One of MindMed’s most valuable assets is its deal with the University Hospital Basel and its research team led by Dr....

By Microdose NewsDesk

Industry

9 Mar 2023

Are LSD and r-MDMA the Future of Psychedelics? MindMed Says Yes

On March 8th, MindMed CEO Robert Barrow spoke for 30 minutes at the 43rd annual Cowen Healthcare Conference....

By James Hallifax

Industry

11 Jan 2023

Key Takeaways from MindMed’s 2023 Corporate Update

On January 9th, psychedelic medicine company MindMed (Nasdaq: MNMD, NEO:MMED) released its 2023 corporate update....

By James Hallifax

Industry

4 Jan 2023

Top 3 Psychedelic Storylines to Watch in 2023

2022 was a milestone year for the psychedelic industry, and 2023 is shaping up to be an even more paradigm-shifting....

By James Hallifax

Industry

30 Dec 2022

2022 End-of-Year Review: MindMed

Continuing our series of 2022 end-of-year reviews, we take a look at MindMed’s last 12 months....

By Jason Najum

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result